Skip to main content
Fig. 1 | BMC Research Notes

Fig. 1

From: Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model

Fig. 1

Reliability of the neutropenic murine thigh infection model with the innovator of amikacin (BMS) in two independent experiments. The non-significant P value (0.393) from global curve fitting analysis (CFA) indicates that the underlying populations are better described by a single curve, confirming the model’s reliability for testing therapeutic equivalence

Back to article page